There is an urgent need to understand and reverse cognitive impairment. The lack of appropriate animal models combined with the limited knowledge of pathophysiological mechanisms makes the development of new cognition-enhancing drugs complex. Scopolamine is a pharmacologic agent which impairs cognition and functional imaging in a wide range of animal species, similarly to what is seen in cognitive impairment in humans.
Methods:
In this study, using a functional ultrasound (fUS) neuroimaging technique, we monitored the impact of donepezil (DPZ), a potent acetylcholinesterase inhibitor and first-line treatment in patients with mild to moderate Alzheimer's disease, in a scopolamine-induced mouse model.
Results:
We demonstrated that despite its low impact on the cerebral blood volume (CBV) signal, scopolamine injection produced an overall decrease in functional connectivity between various brain areas. In addition, we revealed that DPZ induced a strong decrease in CBV signal without causing a difference in functional connectivity.
Conclusion:
Finally, our work highlighted that DPZ counteracted the impact of scopolamine on functional connectivity changes and confirmed the interest of using pharmaco-fUS imaging on cognitive disorders, both in frequent and rare neurological disorders.
AdlimoghaddamANeuendorffMRoyB, et al. (2018) A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci Ther24: 876–888.
2.
AhnaouAHuysmansHJacobsT, et al. (2014) Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential. Neuropharmacology86: 362–377.
3.
BajoRPusilSLopezME, et al. (2015) Scopolamine effects on functional brain connectivity: A pharmacological model of Alzheimer’s disease. Sci Rep5: 9748.
4.
BakkerAAlbertMSKraussG, et al. (2015) Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin7: 688–698.
5.
BercoffJMontaldoGLoupasT, et al. (2011) Ultrafast compound Doppler imaging: Providing full blood flow characterization. IEEE Trans Ultrason Ferroelectr Freq Control58: 134–147.
6.
ChhatwalJPSchultzAPHeddenT, et al. (2019) Anticholinergic amnesia is mediated by alterations in human network connectivity architecture. Cereb Cortex29: 3445–3456.
7.
ChuangKHNasrallahFA (2017) Functional networks and network perturbations in rodents. Neuroimage163: 419–436.
8.
DeffieuxTDemeneCPernotM, et al. (2018) Functional ultrasound neuroimaging: A review of the preclinical and clinical state of the art. Curr Opin Neurobiol50: 128–135.
9.
DonahueMJStevensRDde BoorderM, et al. (2009) Hemodynamic changes after visual stimulation and breath holding provide evidence for an uncoupling of cerebral blood flow and volume from oxygen metabolism. J Cereb Blood Flow Metab29: 176–185.
10.
DroguerreMDucheneAPicoliC, et al. (2020) Efficacy of THN201, a combination of Donepezil and Mefloquine, to reverse neurocognitive deficits in Alzheimer’s disease. Front Neurosci14: 563.
11.
FerrierJTiranEDeffieuxT, et al. (2020) Functional imaging evidence for task-induced deactivation and disconnection of a major default mode network hub in the mouse brain. Proc Natl Acad Sci USA117: 15270–15280.
12.
GriffantiLWilcockGKVoetsN, et al. (2016) Donepezil enhances frontal functional connectivity in Alzheimer’s disease: A pilot study. Dement Geriatr Cogn Dis Extra6: 518–528.
13.
HegedusNLaszyJGyertyanI, et al. (2015) Scopolamine provocation-based pharmacological MRI model for testing procognitive agents. J Psychopharmacol29: 447–455.
14.
HeitzCEpelbaumSNadjarY (2017) Cognitive impairment profile in adult patients with Niemann pick type C disease. Orphanet J Rare Dis12: 166.
15.
JenkinsBG (2012) Pharmacologic magnetic resonance imaging (phMRI): Imaging drug action in the brain. Neuroimage62: 1072–1085.
16.
KlinkenbergIBloklandA (2010) The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev34: 1307–1350.
17.
KocsisPGyertyanIElesJ, et al. (2014) Vascular action as the primary mechanism of cognitive effects of cholinergic, CNS-acting drugs, a rat phMRI BOLD study. J Cereb Blood Flow Metab34: 995–1000.
LancelotSZimmerL (2010) Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci31: 411–417.
20.
LenzRABakerJDLockeC, et al. (2012) The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology (Berl)220: 97–107.
21.
LogothetisNK (2008) What we can do and what we cannot do with fMRI. Nature453: 869–878.
22.
MaceEMontaldoGCohenI, et al. (2011) Functional ultrasound imaging of the brain. Nat Methods8: 662–664.
23.
MandevilleJBLiuCHVanduffelW, et al. (2014) Data collection and analysis strategies for phMRI. Neuropharmacology84: 65–78.
24.
MontaldoGTanterMBercoffJ, et al. (2009) Coherent plane-wave compounding for very high frame rate ultrasonography and transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control56: 489–506.
25.
MorelAPeyrouxELeleuA, et al. (2018) Overview of social cognitive dysfunctions in rare developmental syndromes with psychiatric phenotype. Front Pediatr6: 102.
26.
PennecXCachierPAyacheN (1999) Understanding the “demon’s algorithm”: 3D non-rigid registration by gradient descent. In: TaylorCColchesterA (eds) Medical image computing and computer-assisted intervention – MICCAI’99. MICCAI 1999, Lecture Notes in Computer Science. Berlin, Heidelberg: Springer, pp.597–605.
27.
RabutCCorreiaMFinelV, et al. (2019) 4D functional ultrasound imaging of whole-brain activity in rodents. Nat Methods16: 994–997.
28.
RabutCFerrierJBertoloA, et al. (2020) Pharmaco-fUS: Quantification of pharmacologically-induced dynamic changes in brain perfusion and connectivity by functional ultrasound imaging in awake mice. Neuroimage222: 117231.
29.
SauvageJPoreeJRabutC, et al. (2020) 4D Functional imaging of the rat brain using a large aperture row-column array. IEEE Trans Med Imaging39: 1884–1893.
30.
ShahDBlockxIGunsPJ, et al. (2015) Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. Neuroimage109: 151–159.
31.
ShinCYKimHSChaKH, et al. (2018) The effects of donepezil, an Acetylcholinesterase inhibitor, on impaired learning and memory in rodents. Biomol Ther (Seoul)26: 274–281.
32.
StoiljkovicMKelleyCHorvathTL, et al. (2018) Neurophysiological signals as predictive translational biomarkers for Alzheimer’s disease treatment: Effects of donepezil on neuronal network oscillations in TgF344-AD rats. Alzheimers Res Ther10: 105.
33.
SunderlandTTariotPNWeingartnerH, et al. (1986) Pharmacologic modelling of Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry10: 599–610.
34.
TeipelSJDrzezgaABartensteinP, et al. (2006) Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer’s disease: A double-blind cross-over trial. Psychopharmacology (Berl)187: 86–94.
35.
United Nations Department of Economic and Social Affairs (2020) World Population Ageing 2020 Highlights: Living arrangements of older persons. New York, NY: Author.
36.
UrbanADussauxCMartelG, et al. (2015) Real-time imaging of brain activity in freely moving rats using functional ultrasound. Nat Methods12: 873–878.
37.
UrbanAGolgherLBrunnerC, et al. (2017) Understanding the neurovascular unit at multiple scales: Advantages and limitations of multi-photon and functional ultrasound imaging. Adv Drug Deliv Rev119: 73–100.
38.
VidalBDroguerreMValdebenitoM, et al. (2020a) Pharmaco-fUS for characterizing drugs for Alzheimer’s disease – The case of THN201, a drug combination of donepezil plus mefloquine. Front Neurosci14: 835.
39.
VidalBDroguerreMVenetL, et al. (2021) Inter-subject registration and application of the SIGMA rat brain atlas for regional labeling in functional ultrasound imaging. J Neurosci Methods355: 109139.
40.
VidalBDroguerreMVenetL, et al. (2020b) Functional ultrasound imaging to study brain dynamics: Application of pharmaco-fUS to atomoxetine. Neuropharmacology179: 108273.
41.
WangTHuangQReimanEM, et al. (2013) Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: A 24-week, randomized, clinical trial. J Clin Psychopharmacol33: 636–642.
